Cumberland Pharmaceuticals Inc. (CPIX) Q2 FY26 Earnings Call

Apotex monetization funds a multi-year clinical pipeline transition, but future value depends on Afitroban milestones and regulatory progress.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-04
Length22 minutes
EPS$-0.20
Revenue$166458.00

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CPIX earnings ยท Back to CPIX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.